Gilles Freyer, Noelia Martinez-Jañez, B. Kukiełka-Budny, M. Ulanska, Hugues Bourgeois, Montserrat Muñoz, Serafin Morales, Juan Bayo Calero, Laura Cortesi, Tamás Pintér, Markéta Palácová, Nelli Cherciu, Edgar Petru, Johannes Ettl, Cécilia de Almeida, G. Villanova, Romain Raymond, Christine T.T. Minh, Ana Rodrigues, M. Cazzaniga
{"title":"HR阳性/HER2阴性晚期乳腺癌患者的一线化疗:单剂甲氧嘧啶与每周口服长春瑞滨:随机Tempo乳腺癌研究","authors":"Gilles Freyer, Noelia Martinez-Jañez, B. Kukiełka-Budny, M. Ulanska, Hugues Bourgeois, Montserrat Muñoz, Serafin Morales, Juan Bayo Calero, Laura Cortesi, Tamás Pintér, Markéta Palácová, Nelli Cherciu, Edgar Petru, Johannes Ettl, Cécilia de Almeida, G. Villanova, Romain Raymond, Christine T.T. Minh, Ana Rodrigues, M. Cazzaniga","doi":"10.1016/j.breast.2024.103681","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":508684,"journal":{"name":"The Breast","volume":"435 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study\",\"authors\":\"Gilles Freyer, Noelia Martinez-Jañez, B. Kukiełka-Budny, M. Ulanska, Hugues Bourgeois, Montserrat Muñoz, Serafin Morales, Juan Bayo Calero, Laura Cortesi, Tamás Pintér, Markéta Palácová, Nelli Cherciu, Edgar Petru, Johannes Ettl, Cécilia de Almeida, G. Villanova, Romain Raymond, Christine T.T. Minh, Ana Rodrigues, M. Cazzaniga\",\"doi\":\"10.1016/j.breast.2024.103681\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":508684,\"journal\":{\"name\":\"The Breast\",\"volume\":\"435 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Breast\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.breast.2024.103681\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Breast","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.breast.2024.103681","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study